Symetis is a dynamic and growing company that is taking on – and successfully competing with – established players in TAVI, a large and rapidly growing market and one of the most attractive segments of medtech. They specialize in next-generation, surgically implanted replacement aortic valves for the thousands of patients suffering from severe aortic stenosis (a condition that affects 2% of the world population over the age of 65).
The company’s transcatheter aortic heart valvesdeliver best in class performance. They are based on an innovative new approach to design and delivery. The valve is self-sealing and self-seating which means optimal positioning of the valve and a reduction in paravalvular leaks.